UK-based Tissue Regenix Group has signed a 10-year lease agreement on a 21,000 sqft facility to expand processing capacity at its manufacturing base in San Antonio, Texas. The agreement with the tissue engineering company also includes the option to purchase the facility at a later date.
The new facility, situated on adjacent land to the Group’s current 13,700 sqft facility, will be brought on stream in a phased plan to meet the growing commercial demand for the company’s novel product portfolio.
Tissue Regenix’s portfolio leverages innovative tissue engineering platform technologies to develop and commercialise acellular tissue matrices to prevent donor tissue rejection.
Phase one of the expansion will commence immediately with part of the new building being converted into office, distribution and warehouse space, allowing for additional cleanrooms to be built in the original facility, which are expected to be operational by the end of H1 2020.
Over time, it is planned for further processing and packaging cleanrooms to be built in the new facility, therefore, increasing the company’s ability to process more tissue and produce products.
The new facility underpins the company’s strategy of building strategic partnerships, accelerating US market penetration and pursuing geographic expansion opportunities.
Gareth Jones, Interim CEO of Tissue Regenix Group, said: “I am delighted that we have secured this additional facility to support our ambitious growth plans. The group has undertaken a number of operational initiatives in order to increase production capabilities and meet the growing market demand for our products. Having commenced a second shift at the beginning of the year in our current facility in San Antonio, the phased build-out of this new facility will allow us to meet the growing requirements of our customers well into the future.”
Aside from the direct medical applications, tissue engineering has great potential for use in clinical drug trials to bridge the gap between animal testing and human trials.
dCell
The company’s lead technology is the patented process called dCell Technology. This method is a gentle soft tissue decellularisation process, removing DNA and cellular material to reduce the risk of rejection of donor tissue.
Differentiated characteristics:
- Maintaining the natural acellular scaffold of the tissue structure to allow for cellular proliferation
- Supports regeneration of native tissue
- Can be applied to both human or animal tissue sources, no supply issue
- Favourable health economic benefits due to reduced operation time, reduction in rehab activities, no anticoagulant drugs, stored at room temperature
